CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Cytotoxic CD4Signal transduction and targeted therapy · 2026
   Review
2. Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation.Nature · 2026
   Article
3. Searching for a HIV-1 Cure.Theranostics · 2026
   Review
4. Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
   Article
5. Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.Biomarker research · 2025
   Review

Corrections and comments

• Erratum for
  CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.2021

Authors and funding

26 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.